ERADICATE phase 3 study results highlight the potential

Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to...

Related Keywords

Basilea ,Basel Stadt ,Switzerland ,Washington ,United States ,Mikael Saulay ,Marc Engelhardt ,Sarahb Doernberg ,Sarae Cosgrove ,Timothyc Jenkins ,Daniel Ionescu ,Ivan Titov ,Nicholasa Turner ,Harald Seifert ,Vanceg Fowler Jr ,Boiko Atanasov ,Oleksandr Pavlov ,Maziar Assadi Gehr ,Thomasl Holland ,Basel Allschwil ,Mark Jones ,Thomas Holland ,Kamal Hamed ,Data Review Committee ,Drug Administration ,Basilea Pharmaceutica Ltd ,Pharmaceutica Ltd ,Chief Medical Officer ,Associate Professor ,Duke University School ,Review Committee ,New Drug Application ,Breaking Clinical ,Daptomycin With ,Without Optional Aztreonam ,Complicated Staphylococcus ,Double Blind Trial ,Jennifer Smart ,Swiss Stock Exchange Bsln ,Basilea Pharmaceutica Ag ,